Impact of Early PCSK9 Inhibitor on Heart After Acute Myocardium Infarction

Conditions

• Early PCSK9 Inhibitor on Ventricular Remodling

Eligibility Criteria

Sex

ALL

Age

18 Years - 80 Years

Healthy Volunteers

Not accepted

Interventions

• PCSK9 inhibitor （Alirocumab）plus standard medications — DRUG
  PCSK9 inhibitor（Alirocumab） was giving to subjects before PPCI and continued twice a month until 3 month after AMI
• standard medications — DRUG
  standard medications was giving to subjects according guidelines

Study Details

This is a prospect, multi-center, random study to investigate whether early offering PCSK9 inhibitor to acute myocardium infarction(AMI) can alleviate ventricular remodeling after primary percutaneous intervention(PPCI). Totally,twenty acute myocardium infarction subjects will be enrolled in this study after consent information. After randomization, the control group will receive standard therapy for AMI including PPCI. The experiment group will receive first PCSK9 inhibitor before PPCI, then twice a month until 3 months later. Six month after AMI, Myocardial salvage index will be used to evaluate ventricular remodeling. TnI peaking time and LDL control rates also will be recorded and compared.

Key Dates

Start date

Apr 12, 2021

Status verified

May 2025

Primary completion

Oct 31, 2025

Completion

Oct 31, 2025

Study Design

Enrollment

20 participants (estimated)

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Arms

• Active Comparator: standard group
• Experimental: experiment group

Primary Outcome Measure

myocardial salvage index measured by MRI [ Time Frame: one week after PPCI ]

Central Contacts

• Lei Hou, Doctor
  13564868096
  [email protected]